CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SINEW Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SINEW Pharma Inc
14F-5
No.3, Yuanqu Street, Nangang District
Phone: +886 227885365p:+886 227885365 TAIPEI, 115  Taiwan Ticker: 66346634

Business Summary
Sinew Pharma Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of liver disease treatment drugs and pain medication. The Company's main products include fatty liver disease treatment drugs SNP-610, SNP-630, no hepatotoxicity painkillers SNP-810 and antidote SNP-820. The Company's products are in clinical trials.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, General Manager KaiminZhu
Deputy General Manager, Chief Research & Development Officer, Director ZhenghuiXiong
Head of Finance & Accounting ZiwenChen 6/29/2020 6/29/2020
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 52 (As of 12/31/2023)
Outstanding Shares: 71,165,750 (As of 12/31/2023)
Shareholders: 2,431
Stock Exchange: TPO
Fax Number: +886 227885382


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024